J
Jan A. Burger
Researcher at University of Texas MD Anderson Cancer Center
Publications - 543
Citations - 33028
Jan A. Burger is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Chronic lymphocytic leukemia & Ibrutinib. The author has an hindex of 83, co-authored 511 publications receiving 28306 citations. Previous affiliations of Jan A. Burger include University of Texas Health Science Center at Houston & University of Freiburg.
Papers
More filters
Journal ArticleDOI
Safety and Efficacy of Blinatumomab in Combination With a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-positive Leukemia
Rita Assi,Hagop M. Kantarjian,Nicholas J. Short,Naval Daver,Koichi Takahashi,Guillermo Garcia-Manero,Courtney D. DiNardo,Jan A. Burger,Jorge E. Cortes,Nitin Jain,William G. Wierda,Salim Chamoun,Marina Konopleva,Elias Jabbour +13 more
TL;DR: The combination of blinatumomab with a TKI resulted in high overall response rates among 13 patients and may improve outcomes for this high‐risk population, including higher eradication of minimal residual disease and minimize the use of chemotherapy.
Journal ArticleDOI
Treatment of Chronic Lymphocytic Leukemia.
TL;DR: This research presents a novel approach called “ CAR-T cell reprograming,” which exploits the “ cellular “spiking” in the immune response to treat chronic lymphocytic leukemia with a single therapy.
Journal ArticleDOI
The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy.
Dan A. Landau,Clare Sun,Daniel Rosebrock,Sarah E. M. Herman,Joshua A Fein,Mariela Sivina,Chingiz Underbayev,Delong Liu,Julia Hoellenriegel,Sarangan Ravichandran,Mohammed Farooqui,Wandi Zhang,Carrie Cibulskis,Asaf Zviran,Donna Neuberg,Dimitri Livitz,Ivana Bozic,Ignaty Leshchiner,Gad Getz,Jan A. Burger,Adrian Wiestner,Catherine J. Wu,Catherine J. Wu +22 more
TL;DR: The authors report on transcriptional changes in CLL patients treated with ibrutinib and identify early clonal shifts associated with evolution of resistant clones, indicating greater evolutionary capacity, heralding the emergence of drug-resistant clones.
Journal ArticleDOI
Self-enforcing Feedback Activation between BCL6 and Pre-B Cell Receptor Signaling Defines a Distinct Subtype of Acute Lymphoblastic Leukemia
Huimin Geng,Christian Hurtz,Kyle Lenz,Zhengshan Chen,Dirk Baumjohann,Sarah K. Thompson,Natalya A. Goloviznina,Wei Yi Chen,Wei Yi Chen,Jianya Huan,Dorian LaTocha,Erica Ballabio,Gang Xiao,Jae-Woong Lee,Anne Deucher,Zhongxia Qi,Eugene Park,Chuanxin Huang,Rahul Nahar,Soo-Mi Kweon,Seyedmehdi Shojaee,Lai N. Chan,Jingwei Yu,Steven M. Kornblau,Janetta Jacoba Bijl,B. Hilda Ye,K. Mark Ansel,Elisabeth Paietta,Ari Melnick,Stephen P. Hunger,Peter Kurre,Jeffrey W. Tyner,Mignon L. Loh,Robert G. Roeder,Brian J. Druker,Brian J. Druker,Jan A. Burger,Thomas A. Milne,Bill H. Chang,Markus Müschen +39 more
TL;DR: Findings identify a genetically and phenotypically distinct subset of human ALL that critically depends on tonic pre-BCR signaling, and suggest that pre- BCR tyrosine kinase inhibitors are useful for the treatment of patients with pre- BCCR(+) ALL.
Journal ArticleDOI
The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia.
Jennifer R. Brown,Jacqueline C. Barrientos,Paul M. Barr,Ian W. Flinn,Jan A. Burger,Anh Tran,Fong Clow,Danelle F. James,Thorsten Graef,Jonathan W. Friedberg,Kanti R. Rai,Susan O'Brien +11 more
TL;DR: Ibrutinib may enhance CIT efficacy without additive toxicities, providing the rationale for studying this combination in an ongoing phase 3 trial.